Dimethyl[4-(piperazin-1-YL)butyl]amine | 710-17-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Dimethyl[4-(piperazin-1-YL)butyl]amine
• 英文别名: N,N-dimethyl-4-piperazin-1-ylbutan-1-amine
• CAS: 710-17-8
• 化学式: C₁₀H₂₃N₃
• 分子量: 185.313
• InChiKey: XEMCKCKDZSXQPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-乙酰基-5,5-二甲基-1,3-环己二酮 、 Dimethyl[4-(piperazin-1-YL)butyl]amine 以 四氢呋喃 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. Synthesis and structure-relationships of α,α-tetrahydropyranylglycine

  摘要：

  A series of alpha,alpha-cycloalkylglycine sulfonamide compounds of general formula 1 has previously been identified by our group as selective human B-2(hB(2)) receptor antagonists. Here we report the in vitro and in vivo BK antagonist activity of a further evolution of the series, consisting in compounds of the general formula 2, containing either an alkyl piperazine or a 4-alkyl piperidine ring bearing various positively charged groups (R'). These studies unexpectedly revealed quite a flat nanomolar/subnanomolar SAR for the binding affinity, while differences were seen in the in vitro functional activities. We propose that variations in the residence time may explain these results. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.036
• 作为产物：
  描述：

  tert-butyl 4-(4-methoxy-4-oxobutyl)piperazine-1-carboxylate 在 盐酸 、 lithium aluminium tetrahydride 、 magnesium chloride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 27.58h， 生成 Dimethyl[4-(piperazin-1-YL)butyl]amine
  参考文献：
  名称：

  Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. Synthesis and structure-relationships of α,α-tetrahydropyranylglycine

  摘要：

  A series of alpha,alpha-cycloalkylglycine sulfonamide compounds of general formula 1 has previously been identified by our group as selective human B-2(hB(2)) receptor antagonists. Here we report the in vitro and in vivo BK antagonist activity of a further evolution of the series, consisting in compounds of the general formula 2, containing either an alkyl piperazine or a 4-alkyl piperidine ring bearing various positively charged groups (R'). These studies unexpectedly revealed quite a flat nanomolar/subnanomolar SAR for the binding affinity, while differences were seen in the in vitro functional activities. We propose that variations in the residence time may explain these results. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.036

文献信息

• NEW BRADYKININ B1 ANTAGONISTS
  申请人：Madden James

  公开号：US20110201589A1

  公开（公告）日：2011-08-18

  The invention relates to compounds of formula (I) wherein R 1 , R 1a , R 1b , R 2 , R 3 and X, X 1 , X 2 , X 3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  本发明涉及式(I)的化合物，其中R1、R1a、R1b、R2、R3和X、X1、X2、X3的含义如描述和权利要求中所述。所述化合物可用作Bradykinin B1受体拮抗剂。本发明还涉及制备这种化合物的药物组合物，以及作为药物的生产和使用。
• BRADYKININ B1 ANTAGONISTS
  申请人：EVOTEC AG

  公开号：US20140073627A1

  公开（公告）日：2014-03-13

  The invention relates to compounds of formula (I) wherein R 1 , R 1a , R 1b , R 2 , R 3 and X, X 1 , X 2 , X 3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

  本发明涉及公式(I)的化合物，其中R1、R1a、R1b、R2、R3和X、X1、X2、X3的含义如描述和权利要求中所述。所述化合物可用作Bradykinin B1拮抗剂。本发明还涉及制药组合物，制备此类化合物以及作为药物的生产和使用。
• ZELLIGE POLYISOCYANAT-POLYADDITIONSPRODUKTE
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP1379568A1

  公开（公告）日：2004-01-14
• VERFAHREN ZUR HERSTELLUNG VON ZELLIGEN POLYURETHAN(PUR)-GIESSELASTOMEREN AUS LAGERSTABILEN 1,5-NAPHTHALINDIISOCYANAT(NDI)-PREPOLYMEREN
  申请人：Bayer MaterialScience AG

  公开号：EP2212363A1

  公开（公告）日：2010-08-04
• US8623859B2
  申请人：——

  公开号：US8623859B2

  公开（公告）日：2014-01-07